PORT WASHINGTON, NY - September 4, 2018: Pall Corporation, a global leader in filtration, separation and purification, has formed a strategic partnership with Celltheon Corporation, an experienced cell line and expression technology platform development company. This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART™ Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. It is part of Pall’s strategic approach to forming key partnerships that help enable better, safer and faster biologic production.

“The Pall Biotech portfolio was built to support drug manufacturers at all stages of biotherapeutic molecule development and processes to improve biologic production, and ultimately, global health,” said Mario Philips, VP and General Manager of Pall Biotech. “Pall’s strategic partnerships, such as this one with Celltheon, aim to overcome manufacturing challenges with efficient, integrated and cost-effective total solutions.”

“The Celltheon SMART™ Expression Platform is an off-the-shelf, fully validated mammalian cell platform used to develop biologics and it is well complemented by the Pall Biotech line of equipment and services,” said Amita Goel, CEO, founder and chairman of Celltheon. “With the complementary Celltheon and Pall technologies, we can provide an integrated end-to-end solution for research and bioproduction that is cost effective and time efficient. This partnership with Pall Corporation is in line with Celltheon’s mission to expedite drug development and provide solutions for unmet needs in bioprocessing.”

Through the agreement, Celltheon customers will have immediate access to various Pall Biotech upstream and downstream processing technologies, including bioreactors, mixing and storage, downstream technologies, and consumables.


About Pall Corporation

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

For more information visit www.pall.com

Or follow us on social media Google+ - YouTube -   LinkedIn - Twitter - Facebook

About Celltheon Corporation

Celltheon Corporation is focused on cell line and process development for biologics manufacturing. The team offers off-the-shelf, yet customizable solutions for the expression of a wide variety of recombinant proteins via the proprietary Celltheon SMART™ Expression Platform of technologies and services. Celltheon has developed and integrated consistent and high productivity technologies at every step in the upstream bioproduction process. The Celltheon SMART™ Expression Platform has been validated on a number of pre-clinical and clinical stage molecules. Learn more about reducing time and cost to market with the right partner at http://www.celltheon.com

For more information on working with Celltheon, please contact info@celltheon.com

Pall Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications


Pall Media Contact

White Matter Communications

Beth Willers



More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
April 2020
Pall joins a consortium led by Oxford University in fast-tracking clinical trials for a COVID-19 vaccine beginning April 2020.